Quantification of human lithostathine S2-5 forms using the antibody to the N-terminal peptide region.

Abstract

Lithostathine S2-5 inhibits in vitro crystal growth of CaCO3. We developed an antibody against the peptide region responsible for inhibitory effect to determine whether lithostathine S2-5 levels are different in the pancreatic juice of patients with and without chronic pancreatitis. The antibody against the synthetic peptide of the N-terminal end of lithostathine S2-5 detected lithostathine S2-5 but not lithostathine S1 or lithostathine extracted from pancreatic calculi. Lithostathine S2-5 was detected in samples of pancreatic juice protein by immunoblotting using the specific antibody. The concentration of lithostathine S2-5 was compared between control and chronic pancreatitis groups. The mean concentrations of lithostathine S2-5 were significantly (p=0.002) lower in chronic pancreatitis, 16.3 microg/mg of total protein, than in the control, 47.1 microg/mg of total protein. A decreased concentration of lithostathine S2-5 seems to increase the risk of stone formation in the ducts during the course of chronic pancreatitis because of insufficient inhibition of CaCO3 crystal growth.

• Authors: K Yamadera, K Wada, M Goto, K Yokoyama, Y Morita, Y Kitano, I Makino
• Journal: Pancreas (Pancreas) Vol. 16 Issue 4 Pg. 475-80 (May 1998) ISSN: 0885-3177 [Print] United States
• PMID: 9598807 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Calcium-Binding Proteins
• Lithostathine
• Nerve Tissue Proteins
• REG1A protein, human

Topics

• Adult
• Aged
• Calcium-Binding Proteins (analysis, immunology)
• Chronic Disease
• Female
• Humans
• Lithostathine
• Male
• Middle Aged
• Nerve Tissue Proteins
• Pancreatic Juice (chemistry)
• Pancreatitis (metabolism)